Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
- Ichiro Kawashima,
- Van Tsai,
- Scott Southwood,
- Kazutoh Takesako,
- Alessandro Sette,
- Esteban Celis(corresponding author)
- Takara Shuzo Co., Ltd.,
- Epimmune,
- Mayo Clinic College of Medicine and Science
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewSustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>The human carcinoembryonic antigen (CEA) and HER-2/neu are potential target antigens for CTL specific immunotherapy for common malignancies such as breast, lung, colon, and gastric carcinomas. Several CTL epitopes restricted by HLA-A2, the most common human histocompatibility molecule, have been previously reported. However, to develop CTL-based immunotherapies for the general population, it is necessary to identify epitopes restricted by other common histocompatibility alleles. Here, we describe two HLA-A3- restricted CTL epitopes from the CEA and HER-2/neu antigens. HLA-A3 binding synthetic peptides from CEA and HER-2/neu were tested for immunogenicity by in vitro primary CTL induction protocol using peripheral blood mononuclear cells from normal healthy volunteers. One peptide from CEA (CEA[9<sub>61</sub>]: HLFGYSWYK) and one peptide from HER-2/neu (HER2[9<sub>754</sub>]: VLRENTSPK) were shown to induce CTL that was capable of killing a tumor cell line expressing HLA-A3 and the corresponding tumor-associated antigen. Additional MHC binding studies with the most common HLA molecules belonging to the HLA-A3 superfamily (HLA-A*1101, -A*3101, -A*3301, and -A*6801), demonstrated that CEA[9<sub>61</sub>] binds five of five A3 supertype molecules with high affinity, and the HER2[9<sub>754</sub>] epitope was able to bind to four of the same five alleles. These results indicate that these two new CTL epitopes should be immunogenic in individuals expressing either HLA-A3, or other members of the HLA-A3 superfamily.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 431-435 (5 pages)Journal (Volume, Issue Number)
Cancer Research (Volume 59, Issue 2)Publication milestones
- Published - 01/16/1999
Publication status
Published - 01/16/1999
ISSN
0008-5472Publication IDs
- Scopus: 0033556012
- PubMed: 9927058
Access to documents
Publication metrics
Metrics
SciVal
FWCI
4.70
SciVal
Author count
6
SciVal
citations
121
SciVal
Paper percentile
95
SciVal
Top percentile
5
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
PlumX
Captures
46
Citation count
126
Funding Details
FunderFunding number
NIAID
N01AI045241
